睿昂基因(688217) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was RMB 241.87 million, a decrease of 6.33% compared to the previous year[2] - Net profit attributable to the parent company was -RMB 14.46 million, a decline of 282.38% year-on-year[2] - Basic earnings per share were -RMB 0.26, down 285.71% from the previous year[2] - The company's equity attributable to shareholders decreased by 3.72% to RMB 910.56 million[3] Assets and Impairments - Total assets at the end of the reporting period were RMB 997.11 million, a decrease of 4.51% from the beginning of the period[2] - The company recognized goodwill impairment of RMB 14.30 million, an increase of RMB 6.81 million compared to the previous year[6] - Credit impairment losses on accounts receivable increased by RMB 3.80 million due to slower customer payments[6] Challenges and Costs - The company faced challenges due to the downturn in the medical industry and executive events, impacting revenue expectations[5] - Legal consulting fees related to executive events amounted to RMB 4.51 million, which was not present in the previous year[6] Data Disclaimer - The company emphasizes the preliminary nature of the financial data, which is subject to audit and final confirmation in the annual report[7]